{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:57:38Z","timestamp":1791496658712,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic monoclonal antibodies (t-mAbs) may interfere with electrophoresis-based methods used to monitor multiple myeloma (MM), which can create inaccurate results. Matrix-assisted laser desorption\/ionization time-of-flight (MALDI-TOF) mass spectrometry is an alternative to gels distinguishing between endogenous M-proteins and t-mAbs based on molecular mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples (n = 109) from 34 MM patients receiving Dara-KRd were collected 14 or 28 days postdaratumumab administration. Samples were analyzed using the EXENT\u00ae Analyzer that combines automated immunopurification and MALDI-TOF MS for the isotyping and quantification of monoclonal immunoglobulins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Daratumumab was identified in 103 out of 109 samples (94.5%). In all IgG\u03bb (n = 8), IgA\u03ba (n = 8), and IgA\u03bb (n = 2) patients, the M-protein and daratumumab were detected. Of the IgG\u03ba patients (n = 18), 5 patients had a total of 6 samples where the M-protein was detected but daratumumab was not. There was no difference in the detection rate of daratumumab between samples taken 14 and 28 days postadministration with the median daratumumab concentration being 0.95 and 0.54\u2005g\/L, respectively. A precision study was also performed on 25 replicates containing 1\u2005g\/L daratumumab in serum where a coefficient of variation of 4.2% was observed as determined by the EXENT Analyzer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Immunoglobulin Isotypes (GAM: IgG, IgA, and IgM) for the EXENT Analyzer detected and distinguished a daratumumab kappa light chain peak from an M-protein light chain peak in MM patient serum when resolved by the mass spectrometer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfae142","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T23:30:25Z","timestamp":1732059025000},"page":"235-249","source":"Crossref","is-referenced-by-count":12,"title":["Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System"],"prefix":"10.1093","volume":"10","author":[{"given":"David","family":"Barnidge","sequence":"first","affiliation":[{"name":"The Binding Site, part of Thermo Fisher Scientific , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjay","family":"Sakrikar","sequence":"additional","affiliation":[{"name":"The Binding Site, part of Thermo Fisher Scientific , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Kubicki","sequence":"additional","affiliation":[{"name":"Biological Sciences Division, University of Chicago , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A","family":"Derman","sequence":"additional","affiliation":[{"name":"Biological Sciences Division, University of Chicago , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"Biological Sciences Division, University of Chicago , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Lakos","sequence":"additional","affiliation":[{"name":"The Binding Site, part of Thermo Fisher Scientific , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2025030423061663100_jfae142-B1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4065\/81.5.693","article-title":"Monoclonal gammopathy of undetermined significance, Waldenstr\u00f6m macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment","volume":"81","author":"Rajkumar","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2025030423061663100_jfae142-B2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025030423061663100_jfae142-B3","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025030423061663100_jfae142-B4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/cclm-2019-1105","article-title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins","volume":"58","author":"Jacobs","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2025030423061663100_jfae142-B5","author":"US Food and Drug Administration (FDA)"},{"key":"2025030423061663100_jfae142-B6","doi-asserted-by":"crossref","first-page":"100732","DOI":"10.1016\/j.blre.2020.100732","article-title":"Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity","volume":"46","author":"Diamond","year":"2021","journal-title":"Blood Rev"},{"key":"2025030423061663100_jfae142-B7","doi-asserted-by":"crossref","first-page":"8192","DOI":"10.3390\/ijms21218192","article-title":"Monoclonal antibodies to treat multiple myeloma: a dream come true","volume":"21","author":"D\u2019Agostino","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025030423061663100_jfae142-B8","doi-asserted-by":"crossref","first-page":"e000734","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025030423061663100_jfae142-B9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clml.2017.06.030","article-title":"Monoclonal antibodies in multiple myeloma: a new wave of the future","volume":"17","author":"Sherbenou","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025030423061663100_jfae142-B10","first-page":"70","article-title":"Darzalex (daratumumab): first anti-cd38 monoclonal antibody approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2025030423061663100_jfae142-B11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2017.1322578","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"17","author":"Touzeau","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2025030423061663100_jfae142-B12","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2025030423061663100_jfae142-B13","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1182\/blood-2023-185309","article-title":"Final analysis of a phase 2 trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma (ndmm) without autologous stem cell transplantation (asct)","volume":"142","author":"Derman","year":"2023","journal-title":"Blood"},{"key":"2025030423061663100_jfae142-B14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the manhattan nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025030423061663100_jfae142-B15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinbiochem.2016.09.015","article-title":"Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive m-spikes in peripheral blood","volume":"51","author":"Murata","year":"2018","journal-title":"Clin Biochem"},{"key":"2025030423061663100_jfae142-B16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1515\/cclm-2015-1023","article-title":"Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2025030423061663100_jfae142-B17","author":"US Food and Drug Administration (FDA)"},{"key":"2025030423061663100_jfae142-B18","author":"US Food and Drug Administration (FDA)"},{"key":"2025030423061663100_jfae142-B19","author":"US Food and Drug Administration (FDA)"},{"key":"2025030423061663100_jfae142-B20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2025030423061663100_jfae142-B21","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/jalm\/jfab055","article-title":"Use of a daratumumab-specific immunofixation assay to assess possible immunotherapy interference at a major cancer center: our experience and recommendations","volume":"6","author":"Kirchhoff","year":"2021","journal-title":"J Appl Lab Med"},{"key":"2025030423061663100_jfae142-B22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"key":"2025030423061663100_jfae142-B23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","volume":"81","author":"Mills","year":"2015","journal-title":"Methods"},{"key":"2025030423061663100_jfae142-B24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood"},{"key":"2025030423061663100_jfae142-B25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1373\/jalm.2016.020784","article-title":"Identification of friend or foe: the laboratory challenge of differentiating M-proteins from monoclonal antibody therapies","volume":"1","author":"Mills","year":"2017","journal-title":"J Appl Lab Med"},{"key":"2025030423061663100_jfae142-B26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinbiochem.2021.08.001","article-title":"MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins","volume":"97","author":"Fatica","year":"2021","journal-title":"Clin Biochem"},{"key":"2025030423061663100_jfae142-B27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025030423061663100_jfae142-B28","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/pr5005967","article-title":"Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"key":"2025030423061663100_jfae142-B29","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1021\/acs.jproteome.5b00711","article-title":"Subset of kappa and lambda germline sequences result in light chains with a higher molecular mass phenotype","volume":"14","author":"Barnidge","year":"2015","journal-title":"J Proteome Res"},{"key":"2025030423061663100_jfae142-B30","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jasms.2009.08.020","article-title":"A new method for analysis of disulfide-containing proteins by matrix-assisted laser desorption ionization (MALDI) mass spectrometry","volume":"20","author":"Yang","year":"2009","journal-title":"J Am Soc Mass Spectrom"},{"key":"2025030423061663100_jfae142-B31","author":"ImMunoGeneTics Information System (IMGT)"},{"key":"2025030423061663100_jfae142-B32","author":"Expasy, Swiss Institute of Bioinformatics (SIB)"},{"key":"2025030423061663100_jfae142-B33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025030423061663100_jfae142-B34","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41375-021-01501-0","article-title":"Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab","volume":"36","author":"Abdallah","year":"2022","journal-title":"Leukemia"},{"key":"2025030423061663100_jfae142-B35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","article-title":"MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins","volume":"492","author":"Moore","year":"2019","journal-title":"Clin Chim Acta"},{"key":"2025030423061663100_jfae142-B36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2021.01.021","article-title":"Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy","volume":"516","author":"Eveillard","year":"2021","journal-title":"Clin Chim Acta"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/2\/235\/61236623\/jfae142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/2\/235\/61236623\/jfae142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:06:48Z","timestamp":1741111608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/2\/235\/7928608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,19]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfae142","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,19]]}}}